Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer

Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer

Shots:

  • The P-III BEACON CRC study results involves assessing of Braftovi (encorafenib) + Erbitux (cetuximab), with/without Mektovi (binimetinib) vs Erbitux and irinotecan-based therapy in 665 patients with BRAFV600E-mutant metastatic colorectal cancer, prior treated with 1L & 2L therapies
  • P-III BEACON CRC study results: Braftovi triplet & doublet, improvement in ORR (26.1% vs 1.9% & 20.4% vs 1.9%); OS (9.0 mos. vs 5.4 mos. & 8.4 mos. vs 5.4mos.); ORR assessed by BICR (34.3% & 22.4%) respectively; triple combination reduces the risk of death by 48%
  • Array’s Braftovi & Mektovi is BRAF kinase & MEK inhibitor respectively while Eli Lilly’s Erbitux is an EGFR inhibitor. In Aug’18 the triplet combination therapy receives FDA’s BT designation & plans to submit results of the BEACON CRC study for marketing approval in H2’19

Click here to read full press release/ article | Ref: Array Biopharma | Image: Condit Exhibits